An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation

This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

Start Date07 Aug 2024

Sponsor / Collaborator

Shanghai Allist Pharmaceuticals Co., Ltd.

CTR20241931

/ RecruitingPhase 3

JAB-21822联合JAB-3312对比替雷利珠单抗联合培美曲塞+卡铂一线治疗KRAS p.G12C突变的晚期非鳞状非小细胞肺癌的随机、阳性对照、开放标签的多中心Ⅲ期临床试验

[Translation] A randomized, active-controlled, open-label, multicenter phase III clinical trial of JAB-21822 combined with JAB-3312 versus tislelizumab combined with pemetrexed and carboplatin as first-line treatment for advanced non-squamous non-small cell lung cancer with KRAS p.G12C mutation

评价JAB-21822联合JAB-3312对比一线治疗KRAS p.G12C突变的晚期非鳞状非小细胞肺癌受试者的PFS

[Translation]

To evaluate the PFS of JAB-21822 plus JAB-3312 compared with first-line treatment in patients with advanced non-squamous NSCLC with KRAS p.G12C mutation

Start Date18 Jul 2024

Sponsor / Collaborator

Beijing Jiakesi New Drug Development Co. Ltd.

NCT05288205

/ RecruitingPhase 1/2

A Phase 1/2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of JAB-21822 in combination with JAB-3312 in patients with advanced solid tumors harboring KRAS p.G12C mutation and to determine the RP2D for the combination therapy. In the dose expansion phase, preliminary efficacy and safety of the combination therapy at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.

Start Date14 Apr 2022

Sponsor / Collaborator

Shanghai Allist Pharmaceuticals Co., Ltd.

100 Clinical Results associated with Sitneprotafib

100 Translational Medicine associated with Sitneprotafib

100 Patents (Medical) associated with Sitneprotafib

Literatures (Medical) associated with Sitneprotafib

22 Aug 2024·Journal of Medicinal Chemistry

Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment

Article

Author: Xu, Zilong ; Gao, Panliang ; Cai, Yang ; Wang, Yanping ; Han, Huifeng ; Wang, Yinxiang ; Zhang, Wei ; Wu, Xinping ; Long, Wei ; Ma, Cunbo ; Zhang, Lei ; Kang, Di

As an oncogenic phosphatase, SHP2 acts as a converging node in the RTK-RAS-MAPK signaling pathway in cancer cells and suppresses antitumor immunity by passing signals downstream of PD-1. Here, we utilized the extra druggable pocket outside the previously identified SHP2 allosteric tunnel site by the (6,5 fused), 6 spirocyclic system. The optimized compound, JAB-3312, exhibited a SHP2 binding K_d of 0.37 nM, SHP2 enzymatic IC₅₀ of 1.9 nM, KYSE-520 antiproliferative IC₅₀ of 7.4 nM and p-ERK inhibitory IC₅₀ of 0.23 nM. For JAB-3312, an oral dose of 1.0 mg/kg QD was sufficient to achieve 95% TGI in KYSE-520 xenograft model of mouse. JAB-3312 was well-tolerated in animal models, and a close correlation was observed between the plasma concentration of JAB-3312 and the p-ERK inhibition in tumors. Currently, JAB-3312 is undergoing clinical trials as a potential anticancer agent.

News (Medical) associated with Sitneprotafib

19 Mar 2025

·www.prnewswire.com

Jacobio Pharma Announces 2024 Annual Results

BEIJING, SHANGHAI and BOSTON, March 19, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320 million cash inflows. By the end of 2024, cash and bank balances and bank credit balances amounted to RMB1.45 billion. Jacobio also announced recent business progress and expected milestones. "2024 is a transforatmive year for Jacobio. We have submitted a New Drug Application (NDA) for the KRAS G12C inhibitor glecirasib and have licensed out the China rights of glecirasib and the SHP2 inhibitor sitneprotafib to our partner. This marks Jacobio's successful transformation from the early R&D stage to an innovation-driven value realization stage," said Dr.Yinxiang Wang, the Chairman and CEO of Jacobio Pharma. "Looking ahead to 2025, glecirasib is expected to receive the official approval for marking, which will continuously generate cash flow to invest in Jacobio' subsequent pipeline." Development of core clinical stage products Glecirasib (JAB-21822, KRAS G12C inhibitor) and sitneprotafib (JAB-3312, SHP2 inhibitor) The commercialization and further clinical development in China of glecirasib and sitneprotafib were licensed to Allist on August 30, 2024. Non-small cell lung cancer (NSCLC) The NDA application of glecirasib monotherapy in second-line and above NSCLC was submitted to the CDE (China Drug Evaluation Center) in May 2024 and the priority review designation was granted in the same month. Glecirasib is expected to be approved in the first half of 2025. The Phase III pivotal trial of glecirasib combined with sitneprotafib in front-line NSCLC enrolled the first patient in China on August 7, 2024. Multi-tumor basket The multi-tumor basket registration phase II trial of glecirasib for the treatment of pancreatic cancer, biliary tract cancer, gastric cancer, small bowel cancer, appendiceal cancer and other indications has been initiated in China. Glecirasib has received orphan drug designation (ODD) from FDA and EMA for pancreatic cancer. Colorectal cancer The Phase III trial of glecirasib mono or in combination with cetuximab in third line was approved by the CDE in May 2024 JAB-23E73 (pan-KRAS inhibitor) The IND (Investigational New Drug) applications were approved in China and the United States in September 2024 The first patient was enrolled in November 2024 The dose escalation phase is expected to be completed in the second half of 2025 JAB-30355 (p53 Y220C activator) The IND application of FIH (first-in-human) global trial of JAB-30355 was approved by the FDA in March 2024 and by the CDE in June 2024. The first patient was enrolled in July 2024 The dose escalation is expected to be completed in the second half of 2025 JAB-8263 (BET inhibitor) The dose escalation for JAB-8263 in solid tumors and hematologic malignancy were completed in the U.S. and China, respectively. The RP2D (phase II recommended doses) was obtained. Dose expansion in patients with myelofibrosis is ongoing. Solid tumor portion with specific biomarkers is being explored. . JAB-2485 (Aurora A inhibitor) A Phase I/IIa global trial of JAB-2485 is ongoing in the U.S. and China. Dose escalation phase is expected to be completed in the first half of 2025 The expansion of monotherapy and combination with chemotherapy are being planned. Development of pre-clinical pipelines JAB-BX467 (HER2-STING iADC) Clinical candidate of HER2-STING iADC has been nominated in the second half of 2024. The IND application is being planned to be submitted in 2026. JAB-BX600 (KRAS G12D ADC) The clinical candidate is expected to be nominated in the second half of 2025. As of December 31, 2024, Jacobio has filed more than 360 patent applications worldwide, including 126 authorized patents. Conference call information Jacobio Pharma will hold a conference call at 9:30 AM (Beijing time) on March 20, 2024. Participants, please register in advance through this link: About Jacobio Pharma Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company's core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio's R&D centers are located in Beijing, Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries. For more information, please visit: SOURCE Jacobio Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2NDAPhase 3Orphan DrugDrug Approval

07 Jan 2025

·www.prnewswire.com

The Registrational Clinical Data of Glecirasib was Published in Nature Medicine

BEIJING, SHANGHAI and BOSTON, Jan. 6, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets announced today that the data from a registrational clinical trial of its independently developed KRAS G12C inhibitor glecirasib has been published in Nature Medicine (impact factor 58.7). In the article, Jaocbio disclosed, for the first time, the complete dataset of glecirasib in KRAS G12C mutant non-small cell lung cancer patients in the second line or above setting. The pivotal phase II trial of glecirasib monotherapy demonstrated impressive efficacy, including the confirmed objective response rate of 47.9% (56/117), a median progression-free survival of 8.2 months, and a median overall survival of 13.6 months. Glecirasib has a manageable safety profile. Gleciasib has a favorable gastrointestinal safety profile compared with other KRAS G12C inhibitors. The new drug application of glecirasib is currently under evaluation by the Center for Drug Evaluation of the National Medical Products Administration of China, and has been granted Priority Review Designation. Dr. Yinxiang Wang, Chairman and CEO of Jacobio, said: "It's our great honor to present the data from our pivotal trial in such as prestigious journal as Nature Medicine. The development of KRAS-related inhibitors is still in the early stages. We will continue to explore registration clinical trials with our partners of glecirasib in combo with SHP2 inhibitor JAB-3312 for the treatment of first-line NSCLC and accelerate the development of our other RAS programs such as Pan-KRAS inhibitor." About Glecirasib Glecirasib is a KRAS G12C inhibitor developed by Jacobio. A number of clinical trials of glecirasib are currently ongoing in China, the United States and Europe for patients with advanced solid tumors harboring KRAS G12C mutation. These include combination therapy trials with SHP2 inhibitor JAB-3312 in NSCLC and with cetuximab in colorectal cancer. The pancreatic cancer indication has obtained orphan drug designation in the United States and breakthrough therapy designation in China. About Jacobio Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform. Please visit us at SOURCE Jacobio Pharma WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Orphan DrugPhase 2Breakthrough TherapyClinical ResultPriority Review

27 Sep 2024

·www.echemi.com

Jacobio Pharma Secures €172 Million: Concerns Over Collaboration Behind Ailis’ Massive Investment Exposed!

On September 27, 2024, Jacobio Pharma (stock code: 1167.HK) attracted a lot of attention in the industry when it officially announced a major cooperation development - the successful acquisition of Shanghai Ellis Pharmaceutical Technology Co., LTD. (stock code: 688578.SH) received up to 172 million yuan in cooperation funds. This payment not only marks the depth and stability of the cooperation between the two parties, but also demonstrates the excellent strength and extensive influence of Gax in the field of innovative drug research and development. The composition of this cooperation is quite remarkable, including a down payment of 150 million yuan, which is a direct reflection of Ellis' high recognition and value of Gax's research and development results. In addition, there is also 22.79 million RMB as research and development cost compensation and other related payments, which will strongly support Gax's continued investment and innovation exploration in subsequent research and development projects. Looking back at the history of cooperation between the two parties, it all began with the signing of a landmark cooperation agreement on August 30, 2024.This initiative not only shows CAx's trust and respect for its partners, but also reflects its firm determination to promote the development of China and even the global medical and health cause. KRAS G12C inhibitor Golelexel, as a star drug in the field of tumor therapy in recent years, has won widespread praise worldwide for its unique mechanism of action and remarkable efficacy. The SHP2 inhibitor JAB-3312 is another effort of GaX in the field of precision medicine, and its precision strike ability for specific targets has brought new hope to many patients with refractory diseases. The introduction of these two drugs will undoubtedly inject new vitality into Ellis' product line and further consolidate its leading position in the pharmaceutical market. It is worth noting that this cooperation not only reflects the depth of cooperation between the two sides in the field of drug research and development, but also indicates that China's pharmaceutical industry is gradually moving toward a new stage of internationalization and high-end. As the global pharmaceutical market continues to integrate and competition intensifies, Chinese pharmaceutical companies are enhancing their core competitiveness by strengthening international cooperation, introducing advanced technology and management experience. The cooperation between Gax and Ellis has undoubtedly set a new benchmark for the internationalization of China's pharmaceutical industry.

AcquisitionLicense out/in

100 Deals associated with Sitneprotafib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
KRAS G12C mutant Non-small Cell Lung Cancer	Phase 3	China	Shanghai Allist Pharmaceuticals Co., Ltd.	07 Aug 2024
Pancreatic Ductal Carcinoma	Phase 2	China	Shanghai Allist Pharmaceuticals Co., Ltd.	14 Apr 2022
Esophageal Squamous Cell Carcinoma	Phase 2	China	Beijing Jiakesi New Drug Development Co. Ltd.	30 Jan 2022
Squamous Cell Carcinoma of Head and Neck	Phase 2	China	Beijing Jiakesi New Drug Development Co. Ltd.	30 Jan 2022
Locally Advanced Malignant Solid Neoplasm	Phase 2	United States	Shanghai Allist Pharmaceuticals Co., Ltd.	23 Mar 2021
Locally Advanced Malignant Solid Neoplasm	Phase 2	United States	AbbVie, Inc.	23 Mar 2021
Non-Small Cell Lung Cancer	Phase 2	United States	Shanghai Allist Pharmaceuticals Co., Ltd.	23 Mar 2021
Advanced Malignant Solid Neoplasm	Phase 1	United States	AbbVie, Inc.	23 Mar 2021
Non-Small Cell Lung Cancer	Phase 1	United States	AbbVie, Inc.	23 Mar 2021
Non-Small Cell Lung Cancer	Discovery	United States	AbbVie, Inc.	23 Mar 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05288205 (ESMO2024) Manual	Phase 1/2	KRAS G12C mutant Non-small Cell Lung Cancer First line \|	102	Glecirasib plus JAB-3312	(lnujqsgufe) = ymgsixpdne eaohqxzxzz (dgeosprevu ) View more	Positive	14 Sep 2024
				Glecirasib plus JAB-3312 (PD-L1 TPS≥50%)	(lnujqsgufe) = hxwzbjptbr eaohqxzxzz (dgeosprevu ) View more
NCT05288205 (PRNewswire) Manual	Phase 1/2	KRAS G12C mutant Non-small Cell Lung Cancer First line	194	JAB-21822+JAB-3312	(sqdoxvtsmw) = bplqxuwbnu ixmyqkfwvr (uofkrjjyag )	Positive	01 Jun 2024
				JAB-21822+JAB-3312 (frontline)	(usrkefmhgf) = yxzwnrohuh pdoehkiqlb (tmhagaztjf ) View more
NCT05288205 (ASCO2024) Manual	Phase 1/2	KRAS G12C mutation Solid Tumors	179	Glecirasib 800 mg	(enwmxrpbfh) = xvipgdlbmq wrfanrukgg (rhjhxjdlnd ) View more	Positive	24 May 2024
NCT05288205 (ESMO 12023 \| ESMO 22023) Manual	Phase 1/2	KRAS G12C mutation Solid Tumors KRAS G12C	60	Glecirasib +JAB-3312	(ztoicvaqge) = zfmvgbfowo ahbkmmqnsf (macdpahqgx ) View more	Positive	22 Oct 2023
				Glecirasib +JAB-3312 (KRAS G12Ci naïve NSCLC)	(wnxgopouci) = umxtkhzhvd qxuhhejgft (klwbgosgyh ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sitneprotafib

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation